It is made available under a CC-BY-NC-ND 4.0 International license .

Transmission roles of symptomatic and asymptomatic COVID-19 cases: a modeling study

Authors:

Jianbin Tan1[†], Yang Ge2[†], Leonardo Martinez3, Jimin Sun4, Changwei Li5, Adrianna Westbrook2, Enfu Chen4, Jinren Pan4, Yang Li6, Feng Ling4, Zhiping Chen4[‡], Hui Huang1[‡], Ye Shen2[‡].

Author affiliations:

1 Sun Yat-Sen University, School of Mathematics, Guangzhou, China;

2 University of Georgia, College of Public Health, Department of Epidemiology and

Biostatistics, Athens, Georgia, United States;

3 Boston University, Department of Epidemiology, Boston, United States;

4 Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China;

5 Tulane University School of Public Health and Tropical Medicine, Department of

Epidemiology, New Orleans, Louisiana, United States;

6 Renmin University of China, School of Statistics, Beijing, China.

[†] Joint first authors; [‡] Joint corresponding Author.

It is made available under a CC-BY-NC-ND 4.0 International license .

1 Key Points

- 2 <u>Question</u>:
- 3 What is the transmissibility of COVID-19 asymptomatic and symptomatic cases, respectively?
- 4 To date, they have not been well quantified in existing literature.
- 5
- 6 <u>Findings</u>:
- 7 The transmissibility of asymptomatic and symptomatic COVID-19 increases with patient age.
- 8 The asymptomatic cases had a 66.72% lower transmissibility rate than symptomatic cases.
- 9
- 10 <u>Meaning</u>:
- 11 The transmissibility of asymptomatic COVID-19 cases is not low. Asymptomatic cases are
- 12 harder to detect compared to symptomatic cases. Consequently, the burden of asymptomatic
- 13 transmission could potentially dominate the spreading in certain scenarios.

It is made available under a CC-BY-NC-ND 4.0 International license .

14 Background

15

16 COVID-19, caused by the novel coronavirus (SARS-CoV-2),[1] is a great threat to human 17 health.[2] Nonpharmaceutical interventions such as social distancing, case isolation and contact 18 quarantines are the most common tools for suppressing the pandemic in many countries where 19 vaccine supplements are limited.[3–5] However, much remains unclear regarding SARS-CoV-2 20 transmissibility which undermined the efforts for tailored interventions.[6,7] COVID-19 patients 21 may present and remain pre-symptomatic, asymptomatic, or symptomatic and transmission may 22 occur at each of these disease states.[8–10] Unlike the transmission caused by symptomatic 23 cases, pre-symptomatic and asymptomatic transmission are hard to detect and difficult to 24 measure as many surveillance systems rely on symptom-based population screening.[8,11–13] 25 Previous case studies suggested that asymptomatic COVID-19 individuals are less infectious 26 than symptomatic cases.[14,15] However, asymptomatic cases may spread for a longer period 27 due to reduced efficiency in case detection.[16] Several studies investigated the silent 28 transmission of SARS-CoV-2, but presented contradictory conclusions with estimated burden 29 ranged from 3% to 79%.[16–18]

30

31 Without sufficient follow-up time, asymptomatic and pre-symptomatic cases are often 32 indistinguishable. Consequently, studies using population-level data to estimate of age-specific 33 transmission and susceptibility parameters commonly falls short of accuracy which potentially 34 explains for the heterogeneous findings from different studies.[19–21] Common issues were modeling without data on observed asymptomatic infection[16–18,22] and inclusion of 35 36 pre-symptomatic cases as part of an asymptomatic classification, [19–21]. Meanwhile, few 37 studies assessing asymptomatic infectiousness and viral load with limited sample sizes fail to 38 capture the transmission dynamics. [14,15,23–30] No studies to date have attempted to combine 39 reliable case symptom classification with age-dependent transmissibility, social contact 40 measures, and susceptibility parameters at the population level to learn the transmission 41 dynamics. However, a comprehensive understanding of the age-specific symptomatic and 42 asymptomatic transmission dynamics at the population level is essential to the evaluation of an 43 epidemic and the creation of responding health policies.

- 45 In this study, we report on a longitudinal cohort of all diagnosed COVID-19 infections, between
- 46 January 8th and February 23nd, 2020, from Zhejiang province, China. All patients without initial
- 47 symptoms were followed by at least 90 days to distinguish between asymptomatic and
- 48 pre-symptomatic cases, an essential procedure rarely implemented by previous studies to ensure
- 49 reliable classification of case symptoms. We then built age-stratified compartmental models to
- 50 study the age-dependent population-level transmission roles of symptomatic and asymptomatic
- 51 COVID-19 cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

52 Methods

53

54 Data sources

55 Zhejiang province is an eastern coastal province adjacent to Shanghai city with a population of 56 approximately 54 million individuals.[31] The first and only major wave of the COVID-19 57 epidemic in Zhejiang began on early January, 2020 and continued until late February, 2020 after 58 which only sporadic single-case events were observed. We included information from all 59 confirmed cases in this major wave (a total of 1342 cases), as well as a follow-up investigation 60 related to all detected asymptomatic infections to distinguish between asymptomatic and 61 pre-symptomatic cases. Individual-level data related to the symptom onset of symptomatic 62 infections, as well as COVID-19 confirmation dates and ages of both symptomatic and asymptomatic cases were collected. On January 23rd ,2020, the provincial government changed 63 64 its infectious disease alert category to the highest level and, on February 1st, began a 65 comprehensive set of interventions.[32] As of April 10th, 2020, the date in which we restricted our data for this analysis, no additional outbreak had been observed. Trained health professionals 66 67 investigated each confirmed case with a predefined questionnaire by which basic health and 68 demographic information were collected.

69

70 Definition of symptomatic and asymptomatic cases

71 All confirmed cases and their close contacts were isolated or quarantined after being identified 72 through contact tracing. During the isolation/quarantine period, cases and their contacts received 73 regular testing and daily symptom screening for fever, cough, and shortness of breath. Tests for 74 case confirmation were conducted using reverse transcription polymerase chain reaction 75 (RT-PCR) or viral genome sequencing on samples from throat swabs (oropharynx and 76 nasopharynx). If a case or contact had a positive test result but without any symptoms, they 77 would be temporarily classified as an asymptomatic/pre-symptomatic case at the time. All cases 78 were followed for at least 90 days after their initial positive test to distinguish between 79 asymptomatic and pre-symptomatic cases. Among these subjects, those who developed 80 symptoms later would receive a final classification as a symptomatic case. Others who had never 81 developed any symptoms between their initial positive test and first subsequent negative PCR 82 test would be classified as asymptomatic cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

83

84 Model structure

85 We divided the total population of Zhejiang province into seven age groups (Figure 1). To 86 consider transmission related to symptomatic and asymptomatic infections among different age groups, our model contained 8 compartments for the i^{th} age group: susceptible population (S^i), 87 exposed contacts (E^i), pre-symptomatic cases (I_{ps}^i , infected but have not yet developed 88 symptoms), symptomatic cases (I_s^i) , asymptomatic cases (I_a^i) , infected but asymptomatic till 89 confirmed/recovery), and removed/recovery groups $(R_{cs}^i, R_{ca}^i, R_h^i)$. We assumed new infections 90 were driven by transmission from compartments of I_{ps}^i , I_s^i and I_a^i in all age groups. 91 92 Asymptomatic cases (I_a^i) were infections without typical symptoms which were often 93 94 untraceable in the clinical survey and, therefore, their contribution to population-level 95 transmission would be underestimated. To account for this, we assumed only a proportion of asymptomatic infections were detected (R_{ca}^{i}) , while others (R_{b}^{i}) would be unconfirmed. We were 96 97 able to observe disease confirmation date but not the date of infection for the period from cases becoming infectious to the diagnosis of COVID-19 (\mathcal{A}_{1}^{i}) in those with confirmed asymptomatic 98

99 infection. Based on the virus shedding pattern of asymptomatic infections reported in previous

100 studies, [13, 15, 33, 34] we assumed that this period should be less than 30 days, after which virus

101 shedding generally ceases, and infection is no longer detectable through pathogen-specific

102 testing.

103

104 To identify age-varying transmissibility and susceptibility, [22] we assumed a time-varying curve for the average contact numbers of i^{th} age group with j^{th} age group (c_t^{ij}) , which is estimated 105 106 with the contact matrix between age groups through surveys conducted in Shanghai.[35,36] We 107 separate the probability of infection into two components: transmissibility (T) and 108 susceptibility (s). We define transmissibility (T) as the infectiousness of one case. Similarly, 109 we define susceptibility (s) as the probability of acquiring infection from an infectious case (T = 1). Therefore, s = 0 corresponds to a situation in which the susceptible individuals are 110 111 immune to the disease. We assumed that case transmissibility would depend on age and the 112 presence of symptoms. To capture the age-dependent pattern, B splines basis functions were

- 113 used to model the variability in age-varying transmissibility smoothly. Finally, the
- 114 compartmental model was fitted to the daily new symptomatic and asymptomatic cases in
- 115 Zhejiang province for each age group with Markov Chain Monte Carlo (MCMC) algorithm.
- 116
- All analyses were implemented in R version 3.5.1. Packages of deSolve,[37] extraDistr,[38] and
- splines[39] were used for model fitting. Unless stated otherwise, the medians of the posterior
- 119 distributions were used as the point estimators of parameters and simulated numbers.
- 120
- 121 *Ethics approval*
- 122 The research protocol was approved by the institutional review board at the Zhejiang Provincial
- 123 Center for Disease Control and Prevention. The study was based on deidentified data.
- 124

It is made available under a CC-BY-NC-ND 4.0 International license .

125 **Results**

126

127 <u>Transmissibility</u>

128 The estimated transmissibility presented an age-dependent difference between symptomatic and 129 asymptomatic infections (Figure 2). While the transmission of symptomatic cases monotonically 130 increased with increasing age, the transmissibility of asymptomatic infection remained low until 131 age 40, after which point it significantly increased with increasing age. The age-varying ratios of 132 the two kinds of transmissibility indicated asymptomatic cases were, on average, 66.72% lower 133 in transmission than symptomatic cases. However, the difference between the two types of 134 infections was not as big in those aged 0-20 and 60+ years old, but became more obvious in the 135 middle-aged group where the ratios were as low as 24.42% and 23.38% for those aged 30-40 and 136 40-50 years old, respectively.

137

138 *<u>The proportion of asymptomatic cases</u>*

In Figure 3, the proportion of asymptomatic cases $\left(\frac{R_h^i + R_{ca}^i}{R_h^i + R_{cs}^i + R_{ca}^i}\right)$ estimated by our model was much 139 140 larger than what was observed in the data. The average proportion of asymptomatic cases was 141 28.22% (95%CI: 22.97% - 34.56%) of the total counts of cases in our model estimation, but was 9.24% in the observed data $\left(\frac{R_{ca}^{i}}{R_{ca}^{i}+R_{ca}^{i}}\right)$. In our estimation from the empirical data, the highest 142 143 proportion of asymptomatic case was among 0-10 (60.18% (95% CI: 53.61% - 66.99%)) and 144 10-20 (57.64% (95%CI: 47.45% – 66.98%)) years old groups. For asymptomatic cases, we further estimated the proportion of cases that failed to be detected $\left(\frac{R_h^l}{R_h^l + R_{e,a}^l}\right)$. In the posterior 145 146 samples, the average proportion of unconfirmed cases in all asymptomatic infections was 147 74.10% (95% CI: 65.85% - 80.72%). The maximum proportion of unconfirmed cases was 148 observed in 20-30 years old at 86.59% (95%CI: 73.64% - 92.19%). 149

150 Symptomatic and asymptomatic transmission

151 To explore the impact of symptomatic and asymptomatic transmission, we present several

152 features of the estimated dynamic of the epidemic and the transmission burden caused by

153 symptomatic and asymptomatic cases in Figure 4. The estimated number of daily new

It is made available under a CC-BY-NC-ND 4.0 International license .

154 transmissions reached a peak around ten days prior to the peak of the daily reported new 155 confirmed cases (Figure 4A). We estimated a substantial number of undetected asymptomatic 156 cases (109 (95%CI: 73 - 164)) were infected before the first asymptomatic case was diagnosed 157 (January 27th) (Figure 4B). New transmissions were nearly eliminated by February 2nd, 2020 158 (Figure 4A), when a comprehensive set of restrictions had been implemented. The peak of the 159 two types of transmission both occurred between January 18th to 22nd (Figure 4C). The average 160 burden of asymptomatic transmission during the major outbreak period was estimated to be 161 12.86% (95% CI: 7.54% - 19.27%). The burden of asymptomatic transmission increased with 162 time, ranging from 7.77% to 16.03% (Figure 4D). Simulation studies were conducted to 163 investigate the dynamic changes in the transmission burden over time during a prolonged 164 epidemic. When the duration of the decreasing process of the contact function (represented by 165 "m") was prolonged by two weeks and each individual's daily contact number was increased by 166 one person during the outbreak period, we found a slower decreasing trend in daily new cases 167 infected by asymptomatic cases compared with that contributed by symptomatic cases. 168 Additional scenarios were generated demonstrating the possibility of asymptomatic transmission 169 dominating the total transmission under different conditions, especially when the duration 170 between symptom onset and disease confirmation for symptomatic infections was shortened and 171 the asymptomatic infections were not controlled.

172

173 Age-depended transmission

174 Within each age group, we observed heterogeneous transmission contributions during different 175 time periods (Figure 5A). Early on in the epidemic, the transmission burden was dominated by 176 persons of 50-60 years old (32.75% from January 8th to January 12th), but the proportion of 177 transmission contribution from people over 60 years old significantly increased over time, 178 surpassing the 50-60 years old and reaching 30.42% by February 1st, 2020. The proportion of 179 transmission contribution among varying age groups was distinct between symptomatic and 180 asymptomatic cases (Figure 5B). The majority of both symptomatic and asymptomatic 181 transmissions were contributed by persons over 30 years old (Table S9). Individuals below 30 182 years old only contributed less than 5% of all symptomatic transmission and approximately 12% 183 of all asymptomatic transmission, respectively, despite representing almost 40% of the entire 184 population. Contributions to asymptomatic transmission among 20-30 and >60 year age groups

- 185 (9.44%, and 31.73%, respectively) were substantially higher than their corresponding
- 186 contributions to symptomatic transmission (3.77%, and 26.55%, respectively). To further
- 187 understand possible age-dependent vaccination strategies, a simulation of seven scenarios was
- 188 conducted to assess the percentage decline in different age groups if one age group were to
- achieve 100% immunity by vaccinations. The results suggested that vaccinations targeting age
- 190 groups above 30 years are likely to be more effective at the population level, with the most
- 191 percentage decline of cases from the entire population achieved by targeting the 50-60 years old
- 192 group. Meanwhile, vaccinating those younger than 30 years old are more likely to benefit their
- 193 own age groups.

It is made available under a CC-BY-NC-ND 4.0 International license .

194 Discussion

195

In our study, we found that asymptomatic cases were over 60% less infectious compared to symptomatic cases. While great efforts like mass screening and strict contact tracing were conducted, our results suggested that a large proportion of asymptomatic infections were still not detected.[40] The burden of asymptomatic transmission was inferior in the early outbreak but could become higher with the continuous spread of COVID-19. Under strained resources, age-specific prevention and control strategies aimed at the middle age population may return greater population-level benefits.

203

204 Current evidence suggests that asymptomatic COVID-19 cases are generally less infectious[14] 205 than cases with symptoms. We found that this difference may partially be explained by patient 206 age. Age may directly impact COVID-19 transmission through virus shedding patterns[15] as 207 discussed in previous studies.[41] Symptoms are commonly mild in children[42] but severe in 208 the elderly.[43] While still debatable,[44] higher severity has been associated with increased 209 shedding of the virus.[45] In our study, symptomatic and asymptomatic cases were most 210 infectious in individuals 60 years old or older. In contrary to the monotonic increasing 211 association between age and transmission in symptomatic cases, there was a plateau of a low 212 degree of transmission in young asymptomatic infections. We suspect older adults are not only 213 the most vulnerable to succumb to COVID-19 but also may be more likely to transmit once 214 infected, regardless of symptom status. Interventions attempting to suppress asymptomatic 215 transmission, such as mask-wearing, should primarily focus on older adults if interventions to the 216 whole community are not feasible.

217

Similar to previous studies, our results suggest a small proportion of asymptomatic cases have
been detected since the start of the COVID-19 pandemic in our setting.[46–48] Symptom-based
screening has limited capability in asymptomatic case detection,[6] while mass pathogen or
immunological-based testing at the population-level consumes tremendous health resources, and
thus is not feasible in most settings. Considering these challenges, age-dependent screening
strategies may be more practical. We found that the highest number of undetected asymptomatic
cases was among young adults aged 20 to 30 years old (Table S7) and the corresponding

It is made available under a CC-BY-NC-ND 4.0 International license .

transmission contribution was significantly higher than that of symptomatic case (Figure 5B).

226 Young people were less likely to adhere to social distancing guidelines, [49] often had mild

symptoms or were asymptomatic after infection,[50] and were not prioritized in prevention and

228 controlling strategies.[51] Meanwhile, younger asymptomatic patients were also more likely to

have normal CAT scan findings, which may further complicate case detection.[12] Case

230 detection of asymptomatic COVID-19 cases based on current control strategies implemented in

this study is alarming.

232

233 Based on the estimated transmission contributions from symptomatic and asymptomatic 234 infections, roughly 13% of infections were associated with asymptomatic transmission and that 235 percentage continuously increased with a prolonged period. The overall burden of transmission 236 was mainly contributed by symptomatic cases at the beginning of the epidemic, but 237 asymptomatic infections appeared to have increasing percentages of subsequent cases later on. 238 Additional simulations suggested that the transmission burden could even be dominated by 239 asymptomatic transmissions under certain circumstances. Therefore, the spreading potential of 240 asymptomatic cases cannot be ignored, especially in the later stages of the epidemic and in 241 regions where social distancing has not been mandated. Meanwhile, potential differences in 242 transmission burden by age groups, as shown in Figure 5 and S6, supports prioritizing 243 age-dependent prevention and control strategies when facing strained resources. As the larger 244 contributor to the transmission of COVID-19, the older age population is not only a highly 245 vulnerable group but should also be the primary target for prevention strategies. Vaccine 246 Strategies prioritizing the population between 30-60 years old are likely to have the most 247 population-level benefits.

248

There are several limitations in this study. First, data collection likely missed potential cases of the epidemic, despite intensified efforts devoted by the local investigation team to trace contacts. Due to this, we introduced a compartment in our model (R_h^i) to adjust for poor case ascertainment and missing cases. Second, transmissibility and susceptibility were two factors related to symptomatic and asymptomatic transmission estimation and can be difficult to capture simultaneously. We used the susceptibility estimates from a previous study[22] as priors in our model to account for this parameter identification problem. Third, the contact survey data we

It is made available under a CC-BY-NC-ND 4.0 International license .

- used in our model were obtained in Shanghai, a city adjacent to Zhejiang province. Although the
- two regions share a similar culture and modes of social activities, there were potential
- uncertainties associated with the discrepancies in contact matrices. To address this limitation, we
- 259 introduced a correction parameter in our model, so these uncertainties were partially adjusted for
- in the analyses.
- 261

262 Conclusion

- 263
- 264 In summary, our results suggest individual-level transmissibility of COVID-19 increases with
- 265 patient age, therefore targeting older age groups with prevention and intervention strategies is
- 266 expected to be more efficient. While asymptomatic cases are difficult to trace, the burden of
- asymptomatic transmission is still sizable and should not be ignored. The results from our study
- 268 can be used to inform policy decisions on pandemic control and safe reopening.

It is made available under a CC-BY-NC-ND 4.0 International license .

269 **References**

- 270 1. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of
- 271 Coronavirus Disease 2019 in China. N Engl J Med. Massachusetts Medical Society;
- 272 2020;382:1708–20.
- 2. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard (12/12/2020)
 [Internet]. [cited 2020 Dec 12]. Available from: https://covid19.who.int
- 3. Ferguson N, Laydon D, Nedjati Gilani G, Imai N, Ainslie K, Baguelin M, et al. Report 9:
- 276 Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare
- 277 demand [Internet]. Imperial College London; 2020 Mar. Available from:
- 278 http://spiral.imperial.ac.uk/handle/10044/1/77482
- 4. Prem K, Liu Y, Russell TW, Kucharski AJ, Eggo RM, Davies N, et al. The effect of control
- 280 strategies to reduce social mixing on outcomes of the COVID-19 epidemic in Wuhan, China: a
- 281 modelling study. The Lancet Public Health. Elsevier; 2020;5:e261–70.
- 5. Lewnard JA, Lo NC. Scientific and ethical basis for social-distancing interventions against
 COVID-19. The Lancet Infectious Diseases. 2020;20:631–3.
- 6. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic Transmission, the Achilles' Heel of Current
 Strategies to Control Covid-19. N Engl J Med. 2020;382:2158–60.
- 286 7. Huff HV, Singh A. Asymptomatic Transmission During the Coronavirus Disease 2019
- Pandemic and Implications for Public Health Strategies. Clinical Infectious Diseases.
 2020;71:2752–6.
- 289 8. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of
- 290 2019-nCoV Infection from an Asymptomatic Contact in Germany. N Engl J Med. Massachusetts
- 291 Medical Society; 2020;382:970–1.
- 9. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First Case of 2019
 Novel Coronavirus in the United States. N Engl J Med. 2020;382:929–36.
- 294 10. Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al. Evidence of
- SARS-CoV-2 Infection in Returning Travelers from Wuhan, China. N Engl J Med.
 2020;382:1278–80.
- 11. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al. Virological
 assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–9.
- 299 12. Kronbichler A, Kresse D, Yoon S, Lee KH, Effenberger M, Shin JI. Asymptomatic patients
- 300 as a source of COVID-19 infections: A systematic review and meta-analysis. International
- 301 Journal of Infectious Diseases. 2020;98:180–6.
- 302 13. Han MS, Seong M-W, Kim N, Shin S, Cho SI, Park H, et al. Viral RNA Load in Mildly
- Symptomatic and Asymptomatic Children with COVID-19, Seoul, South Korea. Emerging
 Infectious Diseases. 2020;26:2497–9.

- 305 14. Gao M, Yang L, Chen X, Deng Y, Yang S, Xu H, et al. A study on infectivity of
 306 asymptomatic SARS-CoV-2 carriers. Respir Med. 2020;169:106026.
- 307 15. Kim SE, Jeong HS, Yu Y, Shin SU, Kim S, Oh TH, et al. Viral kinetics of SARS-CoV-2 in
 308 asymptomatic carriers and presymptomatic patients. Int J Infect Dis. 2020;95:441–3.
- 309 16. Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, et al. The
- 310 implications of silent transmission for the control of COVID-19 outbreaks. PNAS. National
- 311 Academy of Sciences; 2020;117:17513–5.
- 312 17. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection
- 313 facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science.
- 314 2020;368:489–93.
- 315 18. Ferretti L, Wymant C, Kendall M, Zhao L, Nurtay A, Abeler-Dörner L, et al. Quantifying
- 316 SARS-CoV-2 transmission suggests epidemic control with digital contact tracing. Science
- 317 [Internet]. American Association for the Advancement of Science; 2020 [cited 2020 Dec
- 318 21];368. Available from: https://science.sciencemag.org/content/368/6491/eabb6936
- 319 19. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic
- infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci.
- 321 Nature Publishing Group; 2020;63:706–11.
- 322 20. Huang L, Zhang X, Zhang X, Wei Z, Zhang L, Xu J, et al. Rapid asymptomatic transmission
- 323 of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of
- 324 youngsters aged 16-23 years outside Wuhan and characteristics of young patients with
- 325 COVID-19: A prospective contact-tracing study. J Infect. 2020;80:e1–13.
- 326 21. Meng H, Xiong R, He R, Lin W, Hao B, Zhang L, et al. CT imaging and clinical course of
- 327 asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China. J Infect.
 328 2020;81:e33–9.
- 329 22. Davies NG, Klepac P, Liu Y, Prem K, Jit M, CMMID COVID-19 working group, et al.
- Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. Nature
 Publishing Group; 2020;26:1205–11.
- 23. Zhou R, Li F, Chen F, Liu H, Zheng J, Lei C, et al. Viral dynamics in asymptomatic patients
 with COVID-19. International Journal of Infectious Diseases. 2020;96:288–90.
- 24. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med. Massachusetts
 Medical Society; 2020;
- 25. Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the
- 337 severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis.
- 338 2020;20:669–77.

- 26. CDC COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus
- 340 Disease 2019 (COVID-19) United States, February 12-March 16, 2020. MMWR Morb Mortal
- 341 Wkly Rep. 2020;69:343–6.
- 342 27. Kong D, Zheng Y, Wu H, Pan H, Wagner AL, Zheng Y, et al. Pre-symptomatic transmission
 343 of novel coronavirus in community settings. Influenza Other Respir Viruses. 2020;14:610–4.
- 28. Furukawa NW, Brooks JT, Sobel J. Evidence Supporting Transmission of Severe Acute
- 345 Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic. Emerg Infect
- 346 Dis [Internet]. 2020 [cited 2020 Aug 8];26. Available from:
- 347 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323549/
- 348 29. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of
- 349 coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship,
- 350 Yokohama, Japan, 2020. Eurosurveillance [Internet]. 2020 [cited 2020 Apr 5];25. Available
- 351 from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180
- 352 30. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier 353 Transmission of COVID-19. JAMA. American Medical Association; 2020;323:1406–7.
- 555 ITalisilission of COVID-19. JAIMA. American Medical Association, 2020;525:1400–7.
- 354 31. Bureau of Statistics. Zhejiang Provincial Bureau of Statistics: Sixth Census Data [Internet].
- 355 2014 [cited 2020 Jul 30]. Available from:
- 356 http://tjj.zj.gov.cn/art/2014/9/3/art_1530851_20980968.html
- 357 32. Chong KC, Cheng W, Zhao S, Ling F, Mohammad KN, Wang MH, et al. Monitoring disease
- 357 52. Choig Ke, Cheng W, Zhao S, Eng T, Wohanniad KV, Wang WH, et al. Wohtoring disease 358 transmissibility of 2019 novel coronavirus disease in Zhejiang, China. International Journal of
- 359 Infectious Diseases. 2020;96:128–30.
- 360 33. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and immunological
 assessment of asymptomatic SARS-CoV-2 infections. Nat Med. Nature Publishing Group;
 2020;26:1200–4.
- 363 34. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, et al. Clinical Course and Molecular Viral
- 364 Shedding Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a
- 365 Community Treatment Center in the Republic of Korea. JAMA Internal Medicine.
- 366 2020;180:1447–52.
- 367 35. Zhang J, Litvinova M, Liang Y, Wang Y, Wang W, Zhao S, et al. Changes in contact
 368 patterns shape the dynamics of the COVID-19 outbreak in China. Science. 2020;368:1481–6.
- 369 36. Zhang J, Klepac P, Read JM, Rosello A, Wang X, Lai S, et al. Patterns of human social
- 370 contact and contact with animals in Shanghai, China. Scientific Reports. Nature Publishing
- 371 Group; 2019;9:15141.
- 372 37. Soetaert K, Petzoldt T, Setzer RW. Solving Differential Equations in R: Package deSolve.
 373 Journal of Statistical Software. 2010;33:1–25.
- 374 38. Wolodzko T, Wolodzko MT. Package 'extraDistr.' 2017;

- 375 39. Perperoglou A, Sauerbrei W, Abrahamowicz M, Schmid M. A review of spline function
- 376 procedures in R. BMC Medical Research Methodology. 2019;19:46.
- 40. Flaxman S, Mishra S, Gandy A, Unwin HJT, Mellan TA, Coupland H, et al. Estimating the
- 378 effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature. Nature Publishing
- 379 Group; 2020;584:257–61.
- 41. Esposito S, Principi N. To mask or not to mask children to overcome COVID-19. Eur J
 Pediatr. 2020;179:1267–70.
- 42. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among
 Children in China. Pediatrics. American Academy of Pediatrics; 2020;145:e20200702.
- 43. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality
 of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.
 2020;395:1054–62.
- 44. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding
 and transmissibility of COVID-19. Nature Medicine. Nature Publishing Group; 2020;26:672–5.
- 45. Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe
 cases of COVID-19. The Lancet Infectious Diseases. 2020;20:656–7.
- 46. Fauci AS, Lane HC, Redfield RR. Covid-19 Navigating the Uncharted. New England
 Journal of Medicine. 2020;382:1268–9.
- 47. García LF. Immune Response, Inflammation, and the Clinical Spectrum of COVID-19. Front
 Immunol. 2020;11:1441.
- 48. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection□: A Narrative
 Review. Ann Intern Med. 2020;173:362–7.
- 49. Czeisler MÉ, Tynan MA, Howard ME, Honeycutt S, Fulmer EB, Kidder DP, et al. Public
- 398 attitudes, behaviors, and beliefs related to COVID-19, stay-at-home orders, nonessential business
- 399 closures, and public health guidance—United States, New York City, and Los Angeles, May
- 400 5–12, 2020. Morbidity and Mortality Weekly Report. Centers for Disease Control and
 401 Prevention; 2020;69:751.
- 50. Felsenstein S, Hedrich CM. COVID-19 in children and young people. The Lancet
 Rheumatology. Elsevier; 2020;2:e514–6.
- 404 51. Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, et al. COVID-19:
- 405 Towards controlling of a pandemic. The Lancet. 2020;395:1015–8.

It is made available under a CC-BY-NC-ND 4.0 International license .

407	Figures
-----	---------

408

- 409 Figure 1. Compartmental model for SARS-CoV-2 transmission, where "j" represents another
 410 age group different from "i" for the compartments.
- 411
- 412 *Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B)*
- 413 The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age groups.
- 414
- 415 *Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic infections*416 *until February 22nd, 2020 for seven age groups.*
- 417

418 *Figure 4. The estimated dynamics of the epidemic and the transmission burdens from*

419 symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions

420 with 95% credible intervals and the observed numbers of daily reported new confirmed cases

- 421 from January 8th to February 22nd, 2020; (B) The observed numbers of daily reported new
- 422 confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily

423 new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated

424 numbers of infected individuals caused by symptomatic and asymptomatic transmission over

425 time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and


426 *asymptomatic transmissions over different time periods.*

427


428 Figure 5. The burden of transmission caused by different ages. (A) The estimated (contribution)

- 429 ratios of new transmissions from different ages over different time periods; (B) The estimated
- 430 (contribution) ratios of symptomatic and asymptomatic transmission from different ages. The
- 431 contribution ratio of each age group is calculated by the proportion of the transmissions caused
- 432 by the corresponding age group to the number of all transmissions in each transmission type,
- 433 from January 8th to February 1st, 2020.


- 434 Figure 1. Compartmental model for SARS-CoV-2 transmission, where "*j*" represents another
- 435 age group different from "*i*" for the compartments.




- 437 Figure 2. (A) The estimated transmissibility and 95% credible intervals for each age group; (B)
- 438 The ratios of asymptomatic transmissibility to symptomatic transmissibility for seven age
- 439 groups.



- 441 Figure 3. The proportion of asymptomatic infections and unconfirmed asymptomatic
- 442 infections until February 22nd, 2020, for seven age groups. The estimated proportions of
- 443 asymptomatic cases, the proportions of cases that failed to be detected among asymptomatic
- 444 infections (unconfirmed proportions), and the observed proportions of asymptomatic cases are
- 445 defined as: $\frac{R_h^i + R_{ca}^i}{R_h^i + R_{cs}^i + R_{ca}^i}$, $\frac{R_h^i}{R_h^i + R_{ca}^i}$, and $\frac{R_{ca}^i}{R_{cs}^i + R_{ca}^i}$, respectively. The 95% credible intervals for the
- 446 estimated proportions of asymptomatic cases are shown for each age group.



- 448 Figure 4. The estimated dynamics of the epidemic and the transmission burdens from
- 449 symptomatic and asymptomatic cases. (A): The estimated numbers of daily new transmissions
- 450 with 95% credible intervals and the observed numbers of daily reported new confirmed cases
- 451 from January 8th to February 22nd, 2020; (B) The observed numbers of daily reported new
- 452 confirmed symptomatic (R_{cs}) and asymptomatic cases (R_{ca}) and the estimated numbers of daily
- 453 new cases that failed to be detected (R_h) with 95% credible intervals; (C): The estimated
- 454 numbers of infected individuals caused by symptomatic and asymptomatic transmission over
- 455 time, with 95% credible intervals; (D): Corresponding proportions of symptomatic and
- 456 asymptomatic transmissions over different time periods.



It is made available under a CC-BY-NC-ND 4.0 International license .

- 458 Figure 5. The burden of transmission caused by different ages. (A) The estimated (contribution)
- 459 ratios of new transmissions from different ages over different time periods; (B) The estimated
- 460 (contribution) ratios of symptomatic and asymptomatic transmission from different ages. The
- 461 contribution ratio of each age group is calculated by the proportion of the transmissions caused
- 462 by the corresponding age group to the number of all transmissions in each transmission type,
- 463 from January 8th to February 1st, 2020.

